S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Stock Forecast, Price & News

$0.31
0.00 (0.00%)
(As of 02:13 PM ET)
Compare
Today's Range
$0.30
▼
$0.33
50-Day Range
$0.29
▼
$0.45
52-Week Range
$0.26
▼
$1.33
Volume
70,570 shs
Average Volume
336,254 shs
Market Capitalization
$18.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.10
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Oncternal Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
1,160.8% Upside
$4.10 Price Target
Short Interest
Healthy
0.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to ($0.43) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

652nd out of 963 stocks

Pharmaceutical Preparations Industry

295th out of 451 stocks

See Top Rated MarketRank™ Stocks Here

ONCT stock logo

About Oncternal Therapeutics (NASDAQ:ONCT) Stock

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

ONCT Price History

ONCT Stock News Headlines

September 20, 2023 | americanbankingnews.com
Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.com
September 19, 2023 | americanbankingnews.com
Oncternal Therapeutics (NASDAQ:ONCT) Lifted to Buy at HC Wainwright
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 18, 2023 | msn.com
HC Wainwright & Co. Upgrades Oncternal Therapeutics (ONCT)
September 18, 2023 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Innate Pharma (IPHA)
September 17, 2023 | finance.yahoo.com
We're A Little Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
September 9, 2023 | msn.com
Cantor Fitzgerald Reiterates Oncternal Therapeutics (ONCT) Neutral Recommendation
September 7, 2023 | finance.yahoo.com
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
August 12, 2023 | finance.yahoo.com
Q2 2023 Oncternal Therapeutics Inc Earnings Call
August 11, 2023 | finance.yahoo.com
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
August 9, 2023 | markets.businessinsider.com
What Wall Street expects from Oncternal Therapeutics's earnings
August 3, 2023 | finance.yahoo.com
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
August 3, 2023 | finance.yahoo.com
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
July 27, 2023 | finance.yahoo.com
ONCT - Oncternal Therapeutics, Inc.
June 21, 2023 | markets.businessinsider.com
Kyowa Kirin Appoints Gunnar F. Kaufmann, Ph.D., as Chief Research Officer, North America
June 10, 2023 | morningstar.com
Oncternal Therapeutics Inc ONCT Stock Quote
June 8, 2023 | finance.yahoo.com
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
June 6, 2023 | msn.com
HC Wainwright & Co. Reiterates Oncternal Therapeutics (ONCT) Neutral Recommendation
June 6, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Hold Rating for Oncternal Therapeutics (ONCT)
May 31, 2023 | finance.yahoo.com
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
May 10, 2023 | markets.businessinsider.com
BTIG Sticks to Their Buy Rating for Shattuck Labs (STTK)
May 9, 2023 | markets.businessinsider.com
BTIG Keeps Their Buy Rating on Xencor (XNCR)
May 6, 2023 | finance.yahoo.com
Oncternal Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line
May 4, 2023 | msn.com
Oncternal Therapeutics GAAP EPS of -$0.20 in-line, revenue of $0.2M beats by $0.06M
May 4, 2023 | finance.yahoo.com
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
May 4, 2023 | msn.com
Oncternal Therapeutics: Q1 Earnings Insights
See More Headlines
Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONCT Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCT
CUSIP
N/A
CIK
1260990
Web
www.oncternal.com
Phone
(858) 434-1113
Fax
901-844-8075
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.10
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$1.30
Forecasted Upside/Downside
+1,222.6%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-44,170,000.00
Net Margins
-4,985.85%
Pretax Margin
-4,985.85%
Return on Equity
-75.67%
Return on Assets
-67.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.36
Quick Ratio
10.37

Sales & Book Value

Annual Sales
$1.49 million
Price / Sales
12.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.08 per share
Price / Book
0.29

Miscellaneous

Outstanding Shares
58,970,000
Free Float
54,251,000
Market Cap
$18.28 million
Optionable
Not Optionable
Beta
1.54
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. James B. Breitmeyer M.D.Dr. James B. Breitmeyer M.D. (Age 69)
    Ph.D., Pres, CEO & Director
    Comp: $814.67k
  • Dr. Salim Yazji M.D. (Age 54)
    Chief Medical Officer
    Comp: $549.21k
  • Mr. Richard G. Vincent CPA (Age 59)
    CFO & Treasurer
  • Dr. Rajesh Krishnan Ph.D. (Age 50)
    Chief Technology Officer
  • Mr. Chase C. LeavittMr. Chase C. Leavitt (Age 41)
    Gen. Counsel & Sec.
  • Mr. Pablo Urbaneja
    Sr. VP of Corp. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ONCT Stock - Frequently Asked Questions

Should I buy or sell Oncternal Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCT, but not buy additional shares or sell existing shares.
View ONCT analyst ratings or view top-rated stocks.

What is Oncternal Therapeutics' stock price forecast for 2023?

6 brokerages have issued 1-year price targets for Oncternal Therapeutics' stock. Their ONCT share price forecasts range from $1.30 to $9.00. On average, they expect the company's stock price to reach $4.10 in the next twelve months. This suggests a possible upside of 1,222.6% from the stock's current price.
View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts.

How have ONCT shares performed in 2023?

Oncternal Therapeutics' stock was trading at $1.00 on January 1st, 2023. Since then, ONCT shares have decreased by 69.0% and is now trading at $0.31.
View the best growth stocks for 2023 here.

When is Oncternal Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ONCT earnings forecast.

How were Oncternal Therapeutics' earnings last quarter?

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.21 million. Oncternal Therapeutics had a negative net margin of 4,985.85% and a negative trailing twelve-month return on equity of 75.67%.

What other stocks do shareholders of Oncternal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX).

What is Oncternal Therapeutics' stock symbol?

Oncternal Therapeutics trades on the NASDAQ under the ticker symbol "ONCT."

Who are Oncternal Therapeutics' major shareholders?

Oncternal Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.34%), Richmond Brothers Inc. (0.50%), Renaissance Technologies LLC (0.49%) and Acadian Asset Management LLC (0.18%). Insiders that own company stock include Chase C Leavitt, Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent and Salim Yazji.
View institutional ownership trends.

How do I buy shares of Oncternal Therapeutics?

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oncternal Therapeutics' stock price today?

One share of ONCT stock can currently be purchased for approximately $0.31.

How much money does Oncternal Therapeutics make?

Oncternal Therapeutics (NASDAQ:ONCT) has a market capitalization of $18.28 million and generates $1.49 million in revenue each year. The company earns $-44,170,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How can I contact Oncternal Therapeutics?

Oncternal Therapeutics' mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.oncternal.com. The company can be reached via phone at (858) 434-1113, via email at investor.relations@oncternal.com, or via fax at 901-844-8075.

This page (NASDAQ:ONCT) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -